Compare Vertiv Holdings Co (VRT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertiv Holdings Co vs GeneDx Holdings Corp — how do they compare? Vertiv Holdings Co trades at $248.02 (market cap $94.90B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Vertiv Holdings Co is far larger — about 47× GeneDx Holdings Corp's market cap, and Vertiv Holdings Co pays a 0.1% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertiv Holdings Co for 39 Days and GeneDx Holdings Corp for 19 Days on average.
| VRT | WGS | |
|---|---|---|
Market Cap | $94.90B | $2.02B |
Volume | 5,469,277 | 734,640 |
Sector | Industrials | Health |
52-Week High | $376.23 | $167.51 |
52-Week Low | $149.83 | $34.51 |
Typical Hold Time | 39 Days | 19 Days |
Enterprise Value | $95.12B | $2.05B |
Dividend Yield | 0.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertiv (VRT) trades at $246.49, down 2.63% amid bearish technical signals but maintains strong fundamental momentum with consistent earnings beats and robust AI-driven data center demand. The stock shows elevated valuation multiples (P/E 55.77, P/S 8.42) against impressive profitability (ROE 43.94%, net margin 15.09%), while analyst consensus remains overwhelmingly bullish with a $364.94 price target. Recent news highlights Vertiv's strategic positioning in AI infrastructure cooling solutions.
Outlook remains positive given Vertiv's exposure to the $7.6 trillion AI spending boom (Goldman Sachs, Sep 2026), though risks include potential securities law investigations and competitive pressures. The stock offers growth exposure to data center electrification trends, with Q3 2026 earnings (expected EPS $1.82) serving as the next key catalyst.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
